Mural Oncology plc (NASDAQ:MURA - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a drop of 25.2% from the January 15th total of 530,200 shares. Based on an average daily volume of 206,900 shares, the short-interest ratio is currently 1.9 days. Currently, 2.6% of the shares of the stock are short sold.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th.
Get Our Latest Stock Report on Mural Oncology
Mural Oncology Trading Up 0.5 %
NASDAQ MURA traded up $0.02 on Tuesday, hitting $4.31. 60,679 shares of the company's stock were exchanged, compared to its average volume of 193,422. The stock has a 50-day moving average of $3.71 and a 200-day moving average of $3.52. The stock has a market cap of $73.36 million, a price-to-earnings ratio of -0.47 and a beta of 3.90. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.62.
Hedge Funds Weigh In On Mural Oncology
A number of institutional investors have recently modified their holdings of the business. Acorn Capital Advisors LLC bought a new position in Mural Oncology in the fourth quarter valued at about $4,141,000. Renaissance Technologies LLC boosted its stake in shares of Mural Oncology by 17.4% in the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company's stock valued at $768,000 after purchasing an additional 35,403 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company's stock valued at $595,000 after purchasing an additional 4,731 shares during the last quarter. Squarepoint Ops LLC increased its position in Mural Oncology by 1.4% during the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company's stock worth $565,000 after purchasing an additional 2,470 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Mural Oncology in the 3rd quarter valued at approximately $340,000. Institutional investors and hedge funds own 80.21% of the company's stock.
Mural Oncology Company Profile
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Further Reading
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
